Fluorescence virus-guided capturing system of human colorectal circulating tumour cells for non-invasive companion diagnostics
- Kunitoshi Shigeyasu1,
- Hiroshi Tazawa1,2,
- Yuuri Hashimoto1,
- Yoshiko Mori1,
- Masahiko Nishizaki1,
- Hiroyuki Kishimoto1,
- Takeshi Nagasaka1,
- Shinji Kuroda1,
- Yasuo Urata3,
- Ajay Goel4,
- Shunsuke Kagawa1,
- Toshiyoshi Fujiwara1
- 1Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
- 2Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan
- 3Oncolys BioPharma, Inc., Tokyo, Japan
- 4Division of Gastroenterology, Department of Internal Medicine, Charles A. Sammons Cancer Center and Baylor Research Institute, Baylor University Medical Center, Dallas, Texas, USA
- Correspondence to Professor Toshiyoshi Fujiwara, Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan;
- Received 10 February 2014
- Revised 20 April 2014
- Accepted 8 May 2014
- Published Online First 28 May 2014
Background Molecular-based companion diagnostic tests are being used with increasing frequency to predict their clinical response to various drugs, particularly for molecularly targeted drugs. However, invasive procedures are typically required to obtain tissues for this analysis. Circulating tumour cells (CTCs) are novel biomarkers that can be used for the prediction of disease progression and are also important surrogate sources of cancer cells. Because current CTC detection strategies mainly depend on epithelial cell-surface markers, the presence of heterogeneous populations of CTCs with epithelial and/or mesenchymal characteristics may pose obstacles to the detection of CTCs.
Methods We developed a new approach to capture live CTCs among millions of peripheral blood leukocytes using a green fluorescent protein (GFP)-expressing attenuated adenovirus, in which the telomerase promoter regulates viral replication (OBP-401, TelomeScan).
Results Our biological capturing system can image epithelial and mesenchymal tumour cells with telomerase activities as GFP-positive cells. After sorting, direct sequencing or mutation-specific PCR can precisely detect different mutations in KRAS, BRAF and KIT genes in epithelial, mesenchymal or epithelial–mesenchymal transition-induced CTCs, and in clinical blood samples from patients with colorectal cancer.
Conclusions This fluorescence virus-guided viable CTC capturing method provides a non-invasive alternative to tissue biopsy or surgical resection of primary tumours for companion diagnostics.